Sotera Health CoSHC -3.08%74 Return-on-Tangible-Asset is 5.70% as of Mar. 2026, which is 448% above its 10-year median of 1.04. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.34 (Fairly Valued). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Sotera Health Co ranks better than 73.83% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sotera Health Co's annualizedNet Income for the quarter that ended in Mar. 2026 was $106 Mil. Sotera Health Co's average total tangible assets for the quarter that ended in Mar. 2026 was $1,865 Mil. Therefore, Sotera Health Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.70%.
The historical rank and industry rank for Sotera Health Co's Return-on-Tangible-Asset or its related term are showing as below:
SHC'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -18 Med: 1.04 Max: 11.28
Current: 6.51
During the past 8 years, Sotera Health Co's highest Return-on-Tangible-Asset was 11.28%. The lowest was -18.00%. And the median was 1.04%.
SHC's Return-on-Tangible-Asset is ranked better than 73.83% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.325
vs SHC: 6.51
Sotera Health Co (NAS:SHC) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sotera Health Co Return-on-Tangible-Asset Related Terms
Sotera Health Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs VCYT, RDNT, BLLN: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.70% mean?
Sotera Health Co (SHC) has a Return-on-Tangible-Asset of 5.70% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sotera Health Co and its competitors. This is 448% above median its historical median of 1.04. According to the industry distribution chart, Sotera Health Co ranks #56 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 26.2%.
Is Sotera Health Co's Return-on-Tangible-Asset too high?
Sotera Health Co's current Return-on-Tangible-Asset of 5.70% is 448% above median its 10-year median of 1.04. Based on the distribution chart, Sotera Health Co ranks #56 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Return-on-Tangible-Asset compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #56 out of 214 companies for Return-on-Tangible-Asset. This puts Sotera Health Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sotera Health Co and its competitors. Sotera Health Co's current Return-on-Tangible-Asset is 5.70%, which is 448% above median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.34, compared to a current price of $17.48 — trading 7% above its estimated fair value. The current Return-on-Tangible-Asset is 5.70%, which is 448% above median its 10-year median of 1.04. Sotera Health Co's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Return-on-Tangible-Asset is 5.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.48 is trading 7% above its estimated GF Value™ of $16.34.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
Return-on-Tangible-Asset: 5.70% (448% above median its 10-year median of 1.04)
GF Value™: $16.34 vs. price of $17.48 (7% above fair value)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
